

BIG PHARMA DAY 3

How to improve drug discovery research

22-23 SEPTEMBER 2022

Venue:

Didactic Centre of the Faculty of Law and Administration JU

ul. Krupnicza 33A

31-123 Kraków, Poland



AIMS OF THIS MEETING

- the main areas of interest for R+D in biotechnological companies
- recommendations for scientists on how to plan and develop their scientific projects with pharmaceutical application
- how business partners can support early-stage projects in life-science
- the possibilities of co-financing research from public agencies

DAY 1

Time	Topic	Speaker
9:15 – 9:30	<i>Introduction</i>	Gabriela Konopka-Cupiał (CTT CITTRU) Paweł Żołnierczyk (iQure Pharma Inc)
9:30 – 10:15	<i>Fundraising – Role of the Researcher</i>	Paweł Żołnierczyk (iQure Pharma Inc)
10:15 – 10:30	Coffee break	
10:30– 11:15	<i>Collaboration “The Good and The Bad”</i>	Henk de Wilde (iQure Pharma Inc) Paweł Żołnierczyk (iQure Pharma Inc)
11:15 – 12:00	<i>What industry is looking for - working with Biotech and Pharma</i>	Sophie Zettl (Cebina GmbH)
12:00 – 13:00	Lunch	
13:00 – 14:00	<i>Documentation on early-stage drug development</i>	Marcin Kołaczkowski (Jagiellonian University Medical College)
14:00 – 15:00	Discussion session	

DAY 2

Time	Topic	Speaker
9:15 – 9:20	<i>Introduction</i>	
9:20 – 9:40	<i>Endothelial profiling of drug candidates</i>	Dominik Czaplicki (JCET)
9:40 – 10:00	<i>Infrared Microscopy for the Life Sciences: CIRI Beamline</i>	Karolina Kosowska (Solaris)
10:00 – 10:15	Coffee break	
10:15 – 10:50	<i>Public co-funding of life-science research</i>	Dorota Markiewicz-Roszak (Horizontalny Punkt Kontrolny Polska Południowo-Wschodnia) Karolina Nowak (Agencja Badań Medycznych)
10:50 – 11:45	<i>Financial support of biotech projects</i>	Albert Smektalski (Brave Venture Capital) Tomasz Poniński (Montis Capital) Aleksander Kłósek (YouNick)
11:45 – 12:45	Lunch	
12:45 – 14:00	<i>Translation of research</i>	Joanna Lipner (Pikralida Sp. z o.o.) Mikołaj Matłoka (Celon Pharma S.A.) Kamil Sitarz (Ryvu Therapeutics S.A.) Georgii Kachkovskiy (Selvita S.A.) Henk De Wilde (iQure Pharma Inc)
14:00 – 15:00	Discussion session	